• Commitments received for a placement of A$15,991,634 at A$0.145 per share
• Significant participation from North American and European institutional and sophisticated investors
• This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company well capitalised

ADELAIDE, Australia, Feb. 10, 2021 /PRNewswire/...